NCT03864575: An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced ” Cold ” Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with an indication of treatment with anti-PD1 antibodies
Exclusions: Patients with active brain or leptomeningeal metastases

Comments are closed.

Up ↑